

NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING
AGENDA

Hilton Montréal Bonaventure, Montréal, Québec
Saturday, April 29, 2006 - 9:00 a.m. - 3:30 p.m.
Room: Hampstead/Cote St. Luc

Chair: Martin Gleave

-
- 9:00 a.m. **WELCOME** M. Gleave
Approval of Fall Meeting Minutes
Chairman's Report
- 9:10 a.m. **NCIC CTG PHASE III TRIALS: OPEN**
PR.8 B. Donnelly
BL.8 / EORTC 30994 L. Wood/A. Aprikian
BL.10 L. Klotz
- 9:40 a.m. **NCIC CTG PHASE III TRIALS: CLOSED**
PR.7 / PR.7 bone sub study J. Crook/L. Klotz
PR.3 P. Warde
PRP.1 N. Fleshner
PRP.1B – open to accrued patients N. Fleshner
BL.7 (EORTC 30987) E. Winquist/M. Moore
- 9:50 a.m. **NCIC CTG TRIALS APPROVED/PENDING ACTIVATION**
PR.11 L. Klotz
BL.11 L. Lacombe
- 10:05 a.m. **CTSU TRIALS ENDORSED BY NCIC CTG**
*CALGB 90203 NHT Taxotere in high risk localized CaP M. Gleave
CALGB 90202 HT with or without zoledronic acid in hormone naïve met CaP F. Saad
* trial in development
- 10:20 a.m. **BREAK**
- 10:40 a.m. **NCIC CTG IND TRIALS**
IND.154: Phase I OGX-011 + Taxotere (closed) K. Chi
IND.161: Triapine Phase II (closed) J. Knox
IND.165: Randomized Phase II (OGX-011 +/- docetaxel HRPC) K. Chi
IND.167: (BAY 43-9006 prostate) (closed) K. Chi

continued . . .

